3 results
The primary objective of this multicenter, parallel design, prospective, randomized clinical trial, with repeated observations over time, is to compare the clinical, safety, and economic outcomes of V.A.C.® Therapy and SCWT based on an open…
1.3. Study Design Rationale The ATLAS-INH trial (ALN-AT3SC-003) is a multicenter, multinational, randomized, openlabel Phase 3 study designed to demonstrate the efficacy and safety of fitusiran in patients with haemophilia A or B with inhibitory…
Primary ObjectiveThe primary objective is to assess safety and tolerability, describe the dose limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD; in the absence of exceeding the MTD) for…